Skip to content

Screening and Validation of Multi-omics Molecular Biomarkers in Distant Metastatic Papillary Thyroid Carcinoma

Screening and Validation of Multi-omics Molecular Biomarkers in Distant Metastatic Papillary Thyroid Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126602
Enrollment
Unknown
Registered
2026-06-12
Start date
2026-06-12
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary thyroid carcinoma

Interventions

The Distant Metastasis Group:N/A
Non-distant Metastasis Group:N/A

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Thyroid papillary carcinoma (PTC) confirmed by histology, with no restriction on pathological subtypes. 2.Histopathology confirmed distant metastasis (lung, bone, brain, liver, etc.). 3.Eligible for paraffin-embedded tissues or fresh frozen tissues from distant metastatic lesions, with a tumor content >=20% and a necrotic area <30%. 4.Complete clinical-pathological-follow-up data: age, gender, tumor size, multifocality, extracapsular extension, lymph node metastasis, time to first recurrence/metastasis, last follow-up time, disease-specific survival status.

Exclusion criteria

Exclusion criteria: 1.Combine history of other malignant tumors. 2.Preoperative treatment with targeted therapy, external radiotherapy, or systemic chemotherapy. 3.Insufficient tissue from metastatic lesions (FFPE slides 30%.

Design outcomes

Primary

MeasureTime frame
Molecular biomarker;Marker validation and evaluation;

Countries

China

Contacts

Public ContactNiu Yun

China-Japan Friendship Hospital

niu_yun@163.com+86 10 84205612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026